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a  b  s  t  r  a  c  t
The  phorbol  ester  Prostratin  may  either  stimulate  or inhibit  human  immunodeﬁciency  virus-1 (HIV-1)
replication.  Here  we report  that  Prostratin  also exhibits  a similar  dual  action  upon feline immunodeﬁ-
ciency  virus  (FIV)  replication  in  an  IL-2-dependent  feline  CD4+ T-cell  line (MYA-1).  While  withdrawal  of
IL-2  halted  FIV  spread,  Prostratin  rescued  virus  production  and cell viability,  mimicking  the functions  of
the cytokine.  Conversely,  FIV  grew  rapidly  in the presence  of  IL-2  and  this  was  inhibited  by  Prostratin.  In
contrast  to HIV-1,  Prostratin  mediated  inhibition  of  FIV  through  means  other  than  blocking  virus  entry.eywords:
IV
rotein kinase C
rostratin
L-2
IV-1
Co-application  of the  protein  kinase  C  (PKC)  inhibitor  Gö6850  with  Prostratin  reversed  both  the  inhibitory
and  stimulatory  effects,  suggesting  that  PKC  is crucial  for  FIV  replication.
© 2012 Elsevier B.V. Open access under CC BY license.D4+ T-cells
. Introduction
Almost three decades after the discovery of the human immu-
odeﬁciency virus (HIV), acquired immunodeﬁciency syndrome
AIDS) remains an incurable disease and a major public health con-
ern globally (Wainberg and Jeang, 2008). While anti-retroviral
herapies may  curtail viral replication within the infected host,
onsiderable research effort is now being directed towards ﬁnd-
ng a way to clear the latent viral reservoirs within the infected
ndividual in order to effect a cure for the disease (Lewin et al.,
011). Prostratin is a non-tumour-promoting phorbol ester that
timulates protein kinase C (PKC) and exhibits both stimulatory
nd inhibitory effects on HIV-1 replication (Biancotto et al., 2004;
rooks et al., 2003; Gulakowski et al., 1997; Gustafson et al., 1992;
orin et al., 2002; Kulkosky et al., 2001; Rullas et al., 2004; Warrilow
t al., 2006). Treatment with compounds such as Prostratin is thus
Abbreviations: FIV, feline immunodeﬁciency virus; HIV-1, human immunodeﬁ-
iency virus-1; PKC, protein kinase C; IL-2, interleukin-2; PMA, phorbol myristate
cetate.
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Open access under CC BY license.being targeted as a means by which latent reservoirs may  be acti-
vated within the host, enabling them to be targeted for elimination.
There is a pressing need for model systems in which prospective
compounds for use in the elimination of viral reservoirs may  be
evaluated. In this study we  investigate the effect of Prostratin on
the in vitro replication of the feline immunodeﬁciency virus (FIV),
a lentivirus that is closely related to HIV-1 and which causes an
AIDS-like disease in cats (Pedersen et al., 1987).
2. Methods
2.1. Cells, virus and reagents
Feline CD4+ T-cells (MYA-1 cells) (Miyazawa et al., 1989)
were cultured in RPMI 1640 medium supplemented with 10%
foetal bovine serum (FBS), 2 mM glutamine, 100 IU/ml penicillin,
100 g/ml streptomycin and 50 M 2-mercaptoethanol. Actively
growing MYA-1 T-cells were also supplemented with conditioned
medium from a murine cell line (L2.3) transfected with a human
IL-2 expression construct (equivalent to 100 U/ml of recombinant
human IL-2). All media and supplements were obtained from Invi-
trogen Life Technologies Ltd. (Paisley, United Kingdom) except for
the FBS, which was supplied by Perbio (Northumberland, UK). FIV
strain GL8 (Hosie and Jarrett, 1990) was  propagated in MYA-1 T-
cells and stored at −80 ◦C prior to use. Phorbol myristate acetate
(PMA) was supplied by Merck Chemicals UK (Nottingham, UK)  and
Prostratin by Sigma–Aldrich (Gillingham, UK). The PKC inhibitor
Gö6850 was supplied by Tocris (Bristol, UK). Raltegravir (RGV) was
1 esear
o
(
2
c
1
A
i
d
s
R
p
F
o
a
s
i
0
2
M
r
G
s
r
P
F
F
T
F
1
4
C
c
T
a
r
f
b
a
7
u
R
m
F
3
2
c
(
C
b
f
w
C
T
P
w
s
922 C.N. Chan et al. / Virus R
btained from Selleck Chemicals (Houston, TX, USA). Zidovudine
AZT) was supplied by Sigma–Aldrich.
.2. Nucleic acid extraction
The Qiagen (Crawley, UK) DNA Mini kit was used to extract total
ellular DNA in assays. Supernatant FIV RNA was  puriﬁed from
 ml  of culture supernatant using the Qiagen UltraSens Virus kit.
n internal control in the form of puriﬁed cellular RNA from un-
nfected feline CD4+ T-cells was added to all supernatant samples
uring the extraction process. This was to provide a way to mea-
ure the efﬁciency of extraction in order to adjust the estimated FIV
NA copy number per ml  of supernatant. Extracted RNA was  further
rocessed by the Qiagen RNeasy Mini kit to remove contaminating
IV DNA. Manufacturer’s protocols were followed. Contamination
f the extracted RNA were not detected by qPCR in most sample
t all the time points, the exceptions being samples from the IL-2
upplemented, productively infected cells at day 7 and day 10 post
nfection. The quantities of the contaminated DNA were less than
.01% of the quantity of FIV cDNA detected.
.3. Quantitative polymerase chain reaction (qPCR)
Intracellular FIV DNA and supernatant FIV RNA from infected
YA-1 T-cells were quantiﬁed using qPCR. Puriﬁed RNA was
everse transcribed into cDNA using the Roche (Welwyn
arden City, UK) Transcriptor High Fidelity cDNA synthe-
is kit. Manufacturer’s protocol was followed and RNA was
everse transcribed using the random hexamer primer. The
CR primers FIV1360F (5′-GCAGAAGCAAGATTTGCACCA-3′) and
IV1437R (5′-TATGGCGGC CAATTTTCCT3′) plus the Taqman probe
IV1416P (5′-FAM-TGCCTCAAG ATACCATGCTCTACACTGCA-
AMRA-3′) were used to amplify a 78 bp section of the
IV gag gene. Primers and probes which amplify feline
8S rRNA (343-fwd: 5′-CCATTCGAACGTCTGCCCTA-3′;
09-rev: 5′-TCACCC GTGGTCACCATG-3′, and probe: 5′-FAM-
GATGGTAGTCGCCGTGCCTA-TAMRA-3′) were used as internal
ontrol. The primers, probes and templates were combined with
aqMan Universal Master Mix  (Applied Biosystems, Paisley, UK) to
 ﬁnal volume of 20 l per reaction in MicroAmp Optical 96-well
eaction plates (Applied Biosystems). Thermo cycling was  per-
ormed with an initial denaturing step at 95 ◦C for 5 min, followed
y 40 cycles of denaturation at 95 ◦C 15 s; annealing and detection
t 55 ◦C for 60 s and measurements were taken using an ABI
500 thermal cycler (Applied Biosystems). Results were analysed
sing the Sequence Detection Software v1.4 (Applied Biosystems).
elative quantities of expression were calculated using the Ct
ethod. The assay can detect a minimum of 10 copies of spiked
IV plasmid per reaction, equivalent of a theoretical minimum of
50 copies per ml  of supernatant.
.4. Standard PCR
The presence of FIV viral DNA in infected cells was
onﬁrmed by using PCR and the primers LTR forward 3
5′-GCTTAACCGCAAAACCACAT-3′) and GAG reverse 3 (5′-
AAATCTCCTGGCTTGAAGG-3′) amplifying a 466 base pair region
etween the 5′ LTR and gag of the FIV genome. Primers that bind to
eline glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene
ere used as control for equal DNA loading (GAPDH forward–5′-
CTTCATTGACCTCAACTACAT-3′; GAPDH reverse–5′-CCAAAG
TGTCATGGATGACC-3′). All reactions used GoTaq® Flexi DNA
olymerase kit (Promega, USA) as per manufacturer’s protocol
ith the following cycling parameters: An initial denaturation
tep of 3 min  at 95 ◦C was followed by 35 cycles of denaturation at
5 ◦C for 45 s; annealing at 57 ◦C for 45 s and extension at 72 ◦C forch 171 (2013) 121– 128
1 min. The ampliﬁcation was  completed with a ﬁnal extension step
at 72 ◦C for 10 min. PCR products were visualised by 2% agarose gel
electrophoresis followed by ethidium bromide staining.
2.5. Stimulation of FIV production from IL-2 depleted MYA-1
T-cells by Prostratin and other chemicals
MYA-1 T-cells were seeded at a density of 5 × 105 cells/ml in
the absence of IL-2 and 24 h post-seeding the cells were infected
with FIV GL8 at multiplicity of infection (M.O.I.) of 0.01 unless
stated otherwise. They were then washed twice and resuspended
in fresh RPMI without IL-2 supplement. The IL-2 depleted cells
were stimulated with either PMA  (0.08), Prostratin (1 M),  and/or
Gö6850 (2.5 M)  or mock stimulated with solvent M (DMSO)
2 days post-infection (unless otherwise stated). The stimulatory
effects of the phorbol esters were titrated and the concentrations
of 0.08 M PMA  and 1 M Prostratin were selected as optimal. The
concentration of 2.5 M of Gö6850 was used based on (Martiny-
Baron et al., 1993) and is a concentration that has been reported to
block both conventional and novel isoforms of PKC. RGV and AZT
were used at 1 M and 5 M respectively where indicated. Sam-
ples were collected at the indicated time points and the removed
volume was  replaced with a matched volume of medium contain-
ing the appropriate compounds. Samples were stored at −80 ◦C
until the end of the experiment at which time virus levels in the
culture supernatants were measured by either an enzyme-linked
immunosorbent assay (ELISA) for FIV capsid antigen (CA, p24)
(IDEXX PetCheck anti FIV antigen, IDEXX Laboratories, ME,  USA), or
by a non-isotopic reverse transcriptase activity assay (Lenti RT kit,
Cavidi AB, Sweden) as per manufacturer’s instructions. Absorbance
was measured spectophotometrically using a Multiskan Ascent
Plate reader (Labsystems).
2.6. FIV productive infection assay
IL-2-supplemented MYA-1 T-cells were seeded at a density of
5 ×105 cells/ml and infected with FIV GL8 (M.O.I. = 0.01) for 2 h
at 37 ◦C. Cells were then washed and resuspended in medium
supplemented with IL-2 and stimulated with Prostratin (1 M)
and/or Gö6850 (2.5 M)  at 2 days post infection. Supernatant sam-
ples were taken at day 8 post infection to be assayed for reverse
transcriptase activity or FIV p24 concentrations. Cell growth and
viability was  measured by Trypan Blue exclusion assay at day 8
post infection.
2.7. Flow cytometry
Flow cytometry was used to measure expression of FIV receptors
CD134 and CXCR4 on MYA-1 T-cells. 0.5 g of primary antibodies
(the mouse anti-feline CD134 monoclonal antibody 7D6  (Willett
et al., 2007) and the Mouse anti-feline CXCR4 monoclonal antibody
(R&D Systems, Minneapolis, USA)) were used to label their respec-
tive receptors. Secondary staining of the receptors was  performed
using 0.5 g of Rabbit anti-mouse IgG RPE secondary antibody (AbD
Serotec, Oxford, UK). Processed cells were then analysed by ﬂow
cytometry using an EPICS MCS-XL ﬂow cytometer (Beckman Coul-
ter, High Wycombe, UK), with 10,000 events being collected for
each sample in LIST mode. Data was analysed using EXPO 32 ADC
Analysis software (Beckman Coulter).2.8. Statistics
Data was  analysed for statistical signiﬁcance using the one way
analysis of variance (ANOVA) test with the Bonferroni and the
C.N. Chan et al. / Virus Researc
Fig. 1. Prostratin stimulates productive FIV infection from infected, IL-2-depleted
T-cells. (A) IL-2 depleted, FIV GL8-infected (M.O.I. = 0.01) MYA-1 CD4+ T-cells were
stimulated with either PMA, Prostratin (Pro) or mock stimulated (DMSO) 4 days
after infection and virus production was measured by FIV p24 ELISA. (B) DNA was
extracted from FIV infected cells at day 12 post infection and screened by PCR for
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FIV, +IL-2; (3) +FIV, −IL-2, +DMSO; (4) +FIV, −IL-2, +PMA; (5) +FIV −IL-2, +Prostratin,
6) FIV plasmid positive control, (7) dH2O negative control.
ukey post-hoc means comparison tests from OriginPro 8.6 (Origin-
ab Corp., USA) where indicated.
. Results
.1. Effect of phorbol esters on IL-2-depleted T-cells infected with
IV
In the presence of IL-2, FIV replicated in the MYA-1 T-cells,
ith the FIV capsid protein (p24) level in the supernatant reach-
ng a plateau six days post infection (Fig. 1A). When cells were
epleted of IL-2 24 h prior to infection, FIV production was dra-
atically reduced (Fig. 1). The addition of Prostratin or the
umour-promoting phorbol ester, phorbol myristate acetate (PMA),
fter infection to the IL-2-depleted, FIV-infected cells stimulated
irus production (Fig. 1A). Standard PCR was used to conﬁrm the
resence of FIV DNA within the total extracted cellular DNA of
he IL-2-depleted, mock-treated T-cells at the end of the experi-
ent, although it should be noted that this PCR did not conﬁrm the
ntegration of the provirus (Fig. 1B).
To assess the contribution of de novo infection with FIV to
he overall virus production as measured by our assay, a parallel
nfection assay was performed in the presence of the retroviral
ntegrase inhibitor Raltegravir (RGV) and the reverse transcriptase
nhibitor Zidovudine (AZT) at concentrations previously shown to
e effective against FIV (Bisset et al., 2002; Savarino et al., 2007).
he antiretroviral drugs were added 24 h post infection, thus
llowing virus production from cells infected during the initial
noculation but blocking any subsequent reverse transcription and
ntegration. The application of the antiretroviral drugs rendered
IV replication from IL-2-supplemented cells undetectable by p24
LISA (Fig. 2A). Only by using the more sensitive technique of
PCR a residual level of virus production was detected in both
L-2-depleted and antiretroviral-treated, IL-2 supplemented cells
Fig. 2B). In a similar experiment, when IL-2 depleted, infectedh 171 (2013) 121– 128 123
cells were simultaneously treated with RGV and PMA  or Prostratin,
virus replication was  dramatically reduced compared with cells not
treated with RGV (Fig. 2C and D). These results indicate that in our
assay the majority of the virus production driven by IL-2 or by the
phorbol esters was the result of de novo infection of adjacent cells.
3.2. Effect of phorbol esters on MYA-1 CD4+ T-cell growth and
viability
In the absence of exogenous IL-2, cell growth ceased and via-
bility fell to between 20 and 30% within six days (Fig. 3A and C).
In contrast, the addition of exogenous IL-2 maintained the viabil-
ity of the cells at approximately 80% and resulted in a doubling of
cell number over the eight-day period (Fig. 3B and D). The addition
of Prostratin prevented the drop in the viability of IL-2-depleted
cells during the study period (Fig. 3A) and triggered a modest
increase in cell number (Fig. 3B). Furthermore, the addition of Pros-
tratin in the presence of IL-2 had little effect on cell viability but
reduced cell growth, with the treated cultures achieving a ﬁnal
density of 1.1 ×106 cells/ml compared with 1.6 × 106 cells/ml in
the untreated cultures (Fig. 3D). These data concur with previous
observations describing the cytoprotective properties of Prostratin
in human cells (Gustafson et al., 1992; Korin et al., 2002).
3.3. Reactivation of virus production from IL-2-depleted cells by
Prostratin appears to require protein kinase C (PKC)-dependent
signalling
Prostratin is a potent activator of the PKC signalling pathway
in human cells and its ability to reactivate latent HIV-1 has been
attributed to stimulation of this pathway (Williams et al., 2004). We
therefore asked whether the speciﬁc inhibitor of PKC “Gö6850”, a
compound that targets both conventional and novel PKC isoforms,
would inhibit the stimulatory effects of Prostratin in vitro. The
application of Gö6850 (at a concentration of 2.5 M,  which should
inhibit most novel and conventional isoforms of PKC (Martiny-
Baron et al., 1993)) signiﬁcantly reduced the stimulation of FIV
production by Prostratin in IL-2-depleted MYA-1 cells (Fig. 4A).
The ability of exogenous IL-2 to reactivate virus production from
IL-2-depleted cells was similarly abrogated by Gö6850 (Fig. 4A),
indicating a common mechanism of action of Prostratin and IL-2 in
the stimulation of FIV replication. Treatment with Gö6850 also sig-
niﬁcantly reversed the cytoprotective effect of Prostratin and IL-2,
suggesting a correlation between the maintenance of cellular via-
bility and the induction of viral replication (Fig. 4B) and this was
consistent with the vital modulatory role of PKC in T-cell activation
and IL-2-dependent signalling (Isakov and Altman, 2002; Tan and
Parker, 2003).
3.4. In the presence of IL-2, Prostratin inhibits productive
infection with FIV
In addition to its role in reversing HIV-1 latency, Prostratin had
been shown to inhibit productive infection with HIV-1 in human
cells (Biancotto et al., 2004; Kulkosky et al., 2001; Rullas et al.,
2004; Warrilow et al., 2006). We  therefore assessed whether this
phenomenon extended to FIV infection of feline cells. In the pres-
ence of IL-2, Prostratin signiﬁcantly reduced FIV production from
infected MYA-1 CD4+ T-cells in all experiments (Fig. 5A and C).
Furthermore, in two  independent experiments the restriction of
virus production was  reversed completely by the simultaneous
treatment of the cells with Gö6850, while data from two other
independent experiments also showed Gö6850 mediating a rever-
sal of viral restriction but it was not statistically signiﬁcant (Fig. 5C).
These observations suggest that the inhibitory effect required PKC-
dependent signalling. An assessment of cell viability (Fig. 5B and
124 C.N. Chan et al. / Virus Research 171 (2013) 121– 128
Days post infection
0 2 4 6 8 10
F
IV
 p
ro
d
u
c
ti
o
n
p
2
4
 E
L
IS
A
, 
A
4
5
0
n
m
)
0
1
2
3
4 -IL-2
+IL-2
+IL-2+RGV+AZT
no FIV
- IL-2
+RGV
DMSO PMA Pro
0
1
2
3
4
5
6- IL-2
DMSO PMA Pro
R
T
 a
c
ti
v
it
y
 (
A
4
0
5
n
m
)
0
1
2
3
4
5
6
A B
C D
Days post infection
0 2 4 6 8 10
S
u
p
e
rn
a
ta
n
t 
F
IV
 R
N
A
(c
o
p
y
/m
l)
10
3
10
4
10 5
10
6
10
7
10
8
10
9 -IL-2
+IL-2
+IL-2+RGV+AZT
Fig. 2. De novo infection contributes to most of the virus production detected by our assay. MYA-1 T-cells supplemented with or depleted of IL-2 for 24 h were infected with
FIV  GL8 (M.O.I. = 0.01). Virus production was measured using (A) FIV p24 ELISA and (B) qPCR. The antiretrovirals RGV and AZT were added to appropriate samples 24 h after
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representative of two independent experiments. (C) IL-2-depleted MYA-1 CD4+ T-cells were infected with FIV GL8 (M.O.I. = 0.06). Two days after infection the cells were
stimulated with PMA, Prostratin (Pro) or mock stimulated (DMSO). Supernatant was collected at day 10 post-infection and virus production was quantiﬁed by a reverse
transcriptase (RT) activity assay. (D) Parallel experiment to (C) in which RGV was  added to the FIV-infected cells 24 h post-infection and 24 h prior to treatment with PMA  or
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separate experiments, virus production was quantiﬁed at day 8 post-infection by FIV p24 ELISA (C) and the viability of FIV infected cells were assessed by Trypan Blue
exclusion  (D). Each bar represents the mean ± standard error (n = 4) and the data are the combination of two  experiments (*p < 0.05; **p < 0.01).
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Fig. 6. Effect of Prostratin on the expression of CD134 and CXCR4 on CD4+ T-cells. MYA-1 CD4+ T-cells were cultured in IL-2-supplemented medium in the presence of
Prostratin (Pro), Prostratin plus Gö6850 (Pro + Gö6850), or solvent (DMSO). Sequential samples were collected over a 7 day period and the expression of (A) CD134 and (B)
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jected to each of the four treatments (Fig. 7), which further supports
the conclusion that Prostratin is acting post-entry to inhibit FIV
replication.
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Fig. 7. No reduction in intracellular FIV DNA following pre-treatment of CD4+ T-cells
with Prostratin. IL-2 supplemented MYA-1 CD4+ T-cells were pre-incubated with
Prostratin (Pro), Prostratin plus Gö6850, Gö6850 alone or mocked treated (DMSO)
for 24 h before infection with FIV GL8. 2 h post infection the cells were washedXCR4 was quantiﬁed by ﬂow cytometry. Data is representative of three independe
xpression of CD134 (C) and CXCR4 (D) was investigated. Each point represents the
) indicated that Prostratin did not reduce the number of viable
ells and thus the inhibitory effect on virus growth was not the
esult of a non-speciﬁc toxic effect. Importantly, the addition of
ö6850 alone did not increase productive infection relative to mock
timulated cells (Fig. 5A and C), instead virus replication was  signif-
cantly reduced in 2 out of 4 experiments (Fig. 5C) and the viability
f infected cells was signiﬁcantly reduced in all experiments.
Previous studies have suggested that the inhibition of pro-
uctive infection with HIV-1 by Prostratin was  mediated by
he down-regulation of HIV-1 receptors CD4, CCR5 and CXCR4
Biancotto et al., 2004; Kulkosky et al., 2001; Rullas et al., 2004;
arrilow et al., 2006). We  therefore examined the effect of Pros-
ratin on the expression of the FIV receptors CD134 (Shimojima
t al., 2004) and CXCR4 (Willett et al., 1997) on MYA-1 T-cells
n the presence of IL-2 over a 7 day period. The expression of
D134 showed a general decline over the experimental period from
70% to ∼40% positive (Fig. 6A and C), while the expression of
XCR4 on the CD4+ T-cells was relatively low compared with CD134
Fig. 6B and D). Prostratin had variable effects on the expression
f CD134 and CXCR4 between experiments, which was probably
 reﬂection of the nature of the MYA-1 CD4+ T-cells as they cycle
hrough phases of blasting, rapid expansion and then rest. However,
hen Prostratin and Gö6850 were added to the cells, a treatment
hich rescued FIV replication from Prostratin-induced inhibition,
he expression of both CD134 and CXCR4 was dramatically reduced
o below the detection limit of ﬂow cytometry (Fig. 6). The applica-
ion of Gö6850 alone to the cells also rapidly reduced the expression
f both CD134 and CXCR4 (Fig. 6C and D). Thus the ability of Pros-
ratin to inhibit productive infection with FIV cannot be explained
y the down-regulation of expression of either CD134 or CXCR4.
Finally, to assess the effect of Prostratin and Gö6850 on viral
ntry directly, IL-2-supplemented MYA-1 CD4+ T-cells were pre-
ncubated with Prostratin, Prostratin plus Gö6850, Gö6850 orperiments. In an additional experiment the effect of applying Gö6850 alone on the
 ± standard error (n = 3).
DMSO for 24 h prior to infection with FIV. Total cellular DNA
was extracted 2 h post infection and intracellular FIV DNA was
quantiﬁed by qPCR. Results from three independent experiments
indicated that similar amounts of FIV DNA were found in cells sub-twice and total cellular DNA extracted. qPCR amplifying a region of the FIV gag gene
was  performed on the DNA samples and the results were analysed using the Ct
method. The data were relative to the average Ct value of the mock treated (DMSO)
cells. Each bar represents the mean ± standard deviation of the calculated relative
quantities (n = 3) and is representative of three independent experiments.
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. Discussion
Despite advances in the development of antiretroviral drugs,
IV-1 remains a major concern for global public health. Research
nto the molecular biology of HIV-1 and related retroviruses such as
IV (which can be used as a comparative model for HIV) may  lead
o novel means to control or even cure the disease. The curious
ual effect of Prostratin on the growth of HIV-1 has been stud-
ed by various laboratories and Prostratin or other PKC modulating
ompounds could be used potentially to stimulate latent HIV-1
eservoirs within the body (Richman et al., 2009). In this study, we
nvestigated the effect of Prostratin on the replication of FIV in vitro
nd we found many parallels, as well as some differences, between
he interaction of FIV and HIV-1 with their respective host cells.
Viruses often encode accessory genes, the products of which
re used to manipulate the host cell in order to enhance viral
eplication; for example, the HIV-1 Vpr protein mediates cell cycle
rrest in order to increase the transcription of the provirus (Romani
nd Engelbrecht, 2009). However, virus replication is also vulner-
ble to global changes in cell signalling, as demonstrated here
y the effect of withdrawing IL-2 on FIV replication. The reliance
f FIV on the cytokine and signalling of the host cell is analo-
ous to the replication dynamics of HIV-1, which also requires a
-cell activation signal, including those driven by IL-2 (Oswald-
ichter et al., 2004; Stevenson et al., 1990; Williams et al., 2004).
he IL-2-dependency of FIV infection in MYA-1 T-cells mirrors the
ehaviour of CD4+CD25+ T-cells isolated from feline peripheral
lood mononuclear cells, which could be non-productively infected
y FIV in the absence of IL-2 (Joshi et al., 2005). The similarities
etween the two systems suggest that the MYA-1 CD4+ T-cell cul-
ure system described herein reﬂects the characteristics of CD4+
-cells ex vivo. As we are constantly striving to reduce the require-
ent for the use of animals in biomedical research, MYA-1 T-cells
ay  alleviate the need for primary feline CD4+ T cells to perform
nitial validation studies of novel compounds for use in the reversal
f viral latency.
By administering the antiretroviral drugs RGV and AZT post-
nfection, we established that most of the virus produced in our
ssays came from the ability of Prostratin or IL-2 to promote de novo
nfection after an initial burst of virus production. The withdrawal
f IL-2 not only inhibited de novo FIV infection, it also stopped cell
rowth and caused a drop in cell viability. In the absence of IL-2,
rostratin appears to be mimicking the function of IL-2 by rescuing
irus spread and cell viability.
When MYA-1 T-cells were supplemented with IL-2, produc-
ive FIV infection was inhibited by Prostratin. This viral restriction,
lus the aforementioned stimulatory effect of Prostratin are both
eversed by the PKC inhibitor Gö6850, indirectly suggesting that
oth of these processes are mediated by PKC. This mirrors sim-
lar ﬁndings in HIV-1 studies (Williams et al., 2004). PKCs are
ital to T-cell receptor signalling and T-cell activation (Isakov and
ltman, 2002). Because both HIV-1 and FIV target activated CD4+
-cells, the viruses have evolved to exploit the cellular pathway
f T-cell activation by encoding binding sites for several transcrip-
ion factors of the PKC signalling cascade in their genomes: the
IV-1 LTR contains sites for NFAT, NFB, and AP-1, while the FIV
TR contains sites for AP-1, AP-4 and ATF (Sparger et al., 1992;
ang et al., 1999; Thompson et al., 1994). In addition, we  also
bserved that Gö6850 abrogated the enhancement of FIV spread
nd the cyto-protective effect by exogenous IL-2, suggesting that
L-2 and Prostratin may  modulate cell growth and FIV spread by
ignalling through the same PKC-dependent pathway. However,
ö6850 could not reliably inhibit productive infection driven by
L-2. Furthermore, Gö6850 reversed the Prostratin mediated virus
estriction in all bar one experimental replicate. We  believe that
here are two likely explanations for this variability of results:h 171 (2013) 121– 128 127
ﬁrstly, unlike truly transformed cell lines with relatively uniform
growth dynamics, MYA-1 cells retain some of the characteristics
of primary cells as they undergo phases of blasting, expansion
and rest. This variability may  translate to variable cellular PKC
activation levels in between experiments, which give rise to the
variability of the effect of Gö6850 on virus replication. Secondly,
there is considerable redundancy within the IL-2 signalling net-
work. IL-2 may  signal down pathways other than PKC such as the
JAK/STAT5, MAPK and PI3K pathways (Cheng et al., 2011). We  have
found no studies which address directly the effect of PKC block-
age on IL-2 stimulated HIV-1 production and further experimental
work is required to conﬁrm the involvement of the aforementioned
pathways in IL-2-dependent lentivirus production. Future research
should also attempt to directly demonstrate the role of PKC in this
phenomenon and to identify the isoform(s) responsible.
Based on these ﬁndings we  propose that there is an optimal
level of PKC activation for FIV spread and replication. We  specu-
late that in a state of low PKC activation such as after the removal
of exogenous IL-2, Prostratin becomes a substitute for IL-2 and
raises PKC activation back to the optimum level. In contrast, if
the cells are already supplemented with IL-2, the addition of Pros-
tratin would over-stimulate PKC, to the detriment of FIV spread
and replication. What then is the mechanism behind the PKC-
mediated viral restriction? There was no reduction in viability after
the IL-2-supplemented cells were treated with Prostratin, thus it is
unlikely that Prostratin inhibits virus replication by a non-speciﬁc
toxic effect. Prostratin had a variable effect on the expression of
CD134 and CXCR4, which we attribute to the non-uniform nature
of the MYA-1 cell growth. The simultaneous addition of Gö6850
and Prostratin to cells led to the rapid down regulation of both viral
receptors, yet the application of Gö6850 rescued productive infec-
tion from Prostratin-induced inhibition. Thus down-regulation of
the FIV receptors cannot be invoked as a reason to explain the
FIV-inhibitory effect of Prostratin.
The down-regulation of CD4, CCR5 and CXCR4 has been
observed consistently among Prostratin-stimulated human CD4+
T-cells, supporting the hypothesis that Prostratin’s anti-HIV-1
effect is mediated at the viral entry step (Biancotto et al., 2004;
Gulakowski et al., 1997; Kulkosky et al., 2001; Rullas et al., 2004).
Does this suggest that Prostratin blocks HIV-1 and FIV via distinct
mechanisms? While the entry of viral pseudotypes bearing HIV-
1 Env (but not VSV-G protein) is inhibited by Prostratin (Rullas
et al., 2004), blockade of the FIV receptors demonstrated by a
pseudotype assay does not necessarily translate to inhibition of
productive infection (Willett et al., 2009). It is possible that Pros-
tratin induces changes to the viral receptor expression levels
among activated CD4+ T-cells that can disrupt pseudotype entry,
but the magnitude of change is too small to block infection with
replication-competent virus. Further, the data presented herein
demonstrated that 2 h after infection, Prostratin-stimulated cells
contained similar amounts of intracellular viral DNA compared
with mock-treated cells, suggesting that viral entry and reverse
transcription were not affected by Prostratin. This contrasts with
two studies of Prostratin’s effect on HIV-1 infection of human
CD4+ T-cells, which found that reverse transcription and HIV-1 p24
uptake was  inhibited (Biancotto et al., 2004; Warrilow et al., 2006).
These ﬁndings may  indicate that Prostratin has distinct effects on
HIV-1 and FIV infection. Alternatively, differences in the experi-
mental protocol may  account for these discrepancies, for example,
in one of the studies Prostratin was washed off before HIV-1 infec-
tion (Warrilow et al., 2006), whereas in all our experiments the
drugs remained in the supernatant throughout the experiment.
Prolonged exposure to phorbol ester is known to down-regulate
PKC (Liu and Heckman, 1998). However, the down regulation of
PKC by phorbol esters is a highly variable phenomenon, with differ-
ent isoforms of PKC been differentially affected within different cell
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ypes (Liu and Heckman, 1998). Currently we do not know which
KC isoform is down regulated, for how long and by how much in
YA-1 cells. Also we do not know whether any potential PKC down
egulation can inhibit virus replication. Furthermore, we  observed
o evidence of down regulation affecting virus replication when
IV-infected IL-2-depleted cells were treated with PMA  and Pros-
ratin. Moreover, down regulation could not explain the rescue of
irus replication using the PKC-inhibitor Gö6850, which is presum-
bly the functional equivalent of a complete down regulation of
KC. It is possible that there is an as yet uncharacterised PKC-driven
ntiviral mechanism operating in both human and feline cells. The
xistence of an entry-independent inhibitory mechanism mediated
y phorbol esters was proposed previously for HIV-1 when it was
ound that phorbol esters could inhibit virus replication in PBMCs
t concentrations that did not reduce HIV-1 receptor expression
igniﬁcantly (Warrilow et al., 2006). Our discovery of an entry-
ndependent inhibition of FIV by Prostratin in feline cells supports
he existence of such a mechanism.
To our knowledge this is the ﬁrst demonstration of Prostratin’s
ntiviral activity against a virus other than HIV-1. While the iden-
ity of the underlying mechanism in feline cells remains elusive
t present, further research on whether Prostratin’s effect on the
ell and lentivirus replication is warranted, especially if Prostratin
r other PKC-modulatory compounds are to be developed as an
nti-HIV latency treatment.
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